The role of nitric oxide synthases in pemphigus vulgaris in a mouse model by Marquina, M. (Miren) et al.
The role of nitric oxide synthases in pemphigus 
vulgaris in a mouse model 
M. Marquina, A. España, M. Fernández-Galar and M.J. López-Zabalza* 
Departments of Dermatology and *Biochemistry, University Clinic of Navarra, School 
of Medicine, University of Navarra, P.O. 4209, Pamplona 31080, Spain 
  
SUMMARY 
Background: Pemphigus vulgaris (PV) is a blistering autoimmune disease 
characterized by IgG autoantibodies against desmoglein 3. Nitric oxide synthases 
(NOS) may contribute to the increase of inflammation in tissues by the generation of 
nitrotyrosine residues (NTR). 
Objectives: To investigate whether the production of NTR mediated by NOS may 
participate in the development of inflammation and acantholysis in PV. 
Methods: Mice were pretreated or not with NOS, tyrosine-kinase (TK) or nuclear factor 
(NF)-κB inhibitors, and then injected with PV-IgG. PV manifestations were examined 
in all mice. The expression of NTR, constitutive NOS (cNOS) [endothelial NOS 
(eNOS) and neuronal NOS (nNOS)], inducible NOS (iNOS) and NF-κB factor were 
studied in epidermis of mice using immunohistochemical techniques. 
Results: After PV-IgG injection, expressions of NTR, iNOS, eNOS and nNOS 
increased in acantholytic cells, as did nuclear translocation of NF-κB in the basal cells 
of the epidermis. Pretreatment of mice with inhibitors of TK, nNOS and nonselective 
NOS, completely prevented NTR expression and the clinical and histological findings 
of PV in mice. TK inhibitor genistein inhibited both nNOS and iNOS expression on the 
membrane of basal keratinocytes, and nuclear translocation of NF-κB. 
Conclusions: Upregulation of cNOS and iNOS, NTR generation and nuclear 
translocation of NF-KB may contribute to increased inflammation and tissue damage in 
PV lesions. The absence of the clinical and histological findings of PV and NTR 
expression in mice injected with PV-IgG, through pretreatment with TK and nNOS 
inhibitors, provides compelling evidence that these signalling molecules should be 
considered as potential therapeutic targets in PV. 
  
 
 
 
Pemphigus vulgaris (PV) is a blistering autoimmune skin disease, characterized by IgG 
autoantibodies against desmoglein (Dsg) 3 and Dsg1.1–3 Several studies have shown that 
PV-IgG binding to Dsg induces an activation of several intracellular signalling 
pathways, leading to phosphorylation of desmosomal proteins by protein kinases and 
the dissociation of cell– cell attachment.4 We have recently demonstrated in vivo the 
participation of tyrosine kinases (TK) and the phosphoinositide signalling pathway in 
acantholysis in PV using the transfer mouse model.5 These observations provide strong 
support for the role of protein phosphorylation by protein kinases in the molecular 
mechanism of acantholysis. 
Nitric oxide (NO) plays an important role in the physiological regulation of the human 
body.6,7 Also, it may be involved in inflammatory skin diseases.8–12 NO is formed by 
nitric oxide synthase (NOS) enzymes.13 Isomeric forms of NOS have been described. 
Two of these are constitutively expressed in some tissues as endothelial (eNOS) and 
neuronal (nNOS) isoforms, whereas another is an inducible enzyme (iNOS).14 All NOS 
isoforms have been detected in several cells, including keratinocytes.15 NO reacts in the 
cell with the superoxide radical (O2-), yielding peroxynitrite, an unstable metabolite that 
rapidly nitrates tyrosine residues (NTR) on proteins to form the stable end product 
nitrotyrosine.12
On the other hand, activation of the NF-κB⁄Rel transcription factors family, and 
subsequent nuclear translocation of cytoplasmic complexes, plays a key role in 
inflammation through its ability to induce transcription of proinflammatory genes.16 NF-
KB may induce the synthesis of cytokines, chemokines, adhesion molecules, matrix 
metalloproteinases, COX-2 and iNOS.17,18
Currently, in vivo experiments using the iNOS inhibitor 1400W,19 the eNOS inhibitor 
L-NIO,20 the nNOS inhibitor SMTC,21 the nonselective NOS inhibitor L-NMMA22 and 
the NF-κB inhibitor parthenolide23 have been successfully employed to explore the role 
of these signalling molecules in several inflammatory diseases. 
Although some NOS isoforms and NF-κB have been implicated in the mechanism of 
inflammation in animal models, the role of these molecules in PV has not yet been 
explored. Therefore, the aim of the present study was to identify if NOS isoforms take 
part in acantholysis of PV, and if so, to determine their role in this autoimmune 
blistering disease using the passive transfer mouse model. 
 
MATERIALS AND METHODS 
Human sera 
Serum samples were obtained by plasmapheresis from three patients with 
mucocutaneous PV, during active disease states, and from a healthy donor (normal 
human serum, NHS). All patients gave signed consent to use their sera for experimental 
studies. Patients and control sera were tested by indirect immunofluorescence (IF) using 
monkey oesophagus as tissue substrate. The immunological characteristics of these sera 
are presented in Table 1. The ethics committee of the University Clinic of Navarra 
approved the study. 
IgG purification 
IgG fractions from the PV patients and the normal human donor were prepared as 
previously described.24 Briefly, IgG fractions were precipitated with 50% ammonium 
sulfate followed by affinity chromatography on Staphylococcus protein A conjugated to 
agarose beads. Bounded IgG was eluted with 0.2 mol L-1 glycine⁄HCl, pH 3, dialysed 
extensively against phosphate-buffered saline (PBS), pH 7.4, concentrated by 
ultrafiltration (Amicon, Beverly, MA, U.S.A.), filter-sterilized, and stored at -70 °C 
until use. Protein concentration was determined by Bradford assay.25 IgG concentration 
in each fraction was estimated by nephelometry using goat antihuman IgG (Beckman 
Array 360 System, Holliston, MA, U.S.A.). 
  
Detection of anti-Dsg1 and anti-Dsg3 antibodies by immunoprecipitation 
The anti-Dsg1 and anti-Dsg3 activity of the PV and NHS sera was assayed by 
immunoprecipitation of recombinant Dsg3 (rDsg)3 and Dsg1.26 Three microlitres of 
each sera were incubated with 3 µg of rDsg1 and rDsg3 for 1 h at room temperature. 
Protein A conjugated agarose beads were added and subjected to extensive washing 
with 0.1% Triton X-100 in Tris-buffered saline (TBS) containing 3 mmol L-1 of calcium 
prior to elution of the immunoprecipitates from the beads with Laemmli sample buffer 
[2% sodium dodecyl sulphate (SDS) 0.1 mol L-1 Tris, pH 6.8]. Immunoprecipitates 
were separated by 10% SDS–polyacrylamide gel electrophoresis, transferred to 
nitrocellulose membrane, and probed by Western blot analysis using rabbit antihuman 
Dsg1 and antihuman Dsg3 primary antibodies (1 : 2000) and horseradish peroxidase-
conjugated goat antirabbit IgG secondary antibodies (1 : 3000). Immunoreactants were 
developed with the enhanced chemiluminiscence reaction (ECL-Plus system; 
Amersham Pharmacia Biotech, Amersham, Bucks, U.K.). 
 
Detection of anti-Dsg1 and anti-Dsg3 antibodies by enzyme-linked immunosorbent 
assay 
PV and NHS sera were tested for Dsg1 and Dsg3 by a commercially available enzyme-
linked immunosorbent assay (ELISA) kit following the manufacturer’s 
recommendations (MBL Naka-Ku, Nagoya, 460-002, Japan). The ELISA results were 
taken as: negative (≤ 9 units), indeterminate (10– 20 units) and positive (> 20 units). 
 
Testing IgG pathogenicity using the passive transfer animal model 
C57BL⁄6J mice were obtained from The Jackson Lab (Bar Harbor, ME, U.S.A.). The 
study was performed in 24–48-h-old neonatal mice (weighing 1.5–2.0 g) from a colony 
maintained at the Centre of Animal Control at the University of Navarra. Each IgG 
fraction was tested for pathogenicity by passive transfer experiments as previously 
described.24 IgG from all three PV sera and NHS were injected intradermally into neo-
natal mice (2 mg g-1) (n = 3 for each IgG) and evaluated 14 h later for evidence of skin 
blisters. Following examination of the skin for blisters, animals were sacrificed and 
serum was collected for indirect IF assay using monkey oesophagus as substrate. 
Clinical activity in mice was evaluated by the presence of Nikolsky’s sign (Ns), through 
pinching the injected skin, and according to the following scale: no spontaneous disease 
and negative Ns (0), no spontaneous disease and slight Ns (1+), slight spontaneous 
disease and slight Ns (2+) and important spontaneous disease and positive Ns (3+). Skin 
biopsies from each animal included lesional skin samples for routine histological 
examination by haematoxylin and eosin and immunohistochemical staining, and 
perilesional skin samples for direct IF studies. Also, using the three PV sera and the 
serum from the healthy donor we scored the histological findings from the mice using 
the following scale: (0), no acantholysis; (1+), acantholysis affecting < 25% of the 
epidermis; (2+), acantholysis affecting between 25% and 50% of the epidermis; (3+), 
acantholysis affecting > 75% of the epidermis. 
 
Administration of inhibitors 
Each inhibitor was administered to mice by intradermal injection 2 h before intradermal 
injections of PV-IgG. Inhibitors were diluted in PBS and injected into mice (n = 3 for 
each inhibitor) at the following doses based on in vivo studies reported elsewhere: TK 
inhibitor genistein, 500 µg g-1 body weight (Sigma, St Louis, MO U.S.A., G6649);5 
iNOS inhibitor 1400W, 3 µg g-1 body weight (Calbiochem, Darmstadt, Germany, 
100050);19 eNOS inhibitor L-NIO [L-N5-(1-Iminoethyl) ornitine dihydrochloride], 30 
µg g-1 body weight (Calbiochem, 400600);20 nNOS inhibitor SMTC (S-methyl-L-
thiocitruline dihdrochloride), 50 µg g-1 body weight (Calbiochem, 472804);21 
nonselective NOS inhibitor L-NMMA [N(G) monomethyl-L-arginine], 0.5 µg g-1 body 
weight (Calbiochem, 475886);22 NF-KB inhibitor parthenolide, 6 µg g-1 body weight 
(Calbiochem, 512732).23 
 
Immunohistochemical staining 
Paraffin sections 5-µm thick were mounted on slides coated with Vectabond (SP-1800; 
Vector Laboratories, Burlingame, CA, U.S.A.). These sections were dewaxed with 
xylene and rehydrated with graded ethanol. Endogenous peroxidase activity was 
blocked with 3% hydrogen peroxidase for 10 min. Before the immunohistochemical 
analyses were performed, all antibodies except eNOS required antigen retrieval. All 
sections were placed in a citrate buffer 0.01 mol L-1 (pH 6.0) and heated in a microwave 
oven (Balay W-2112, 1150-700W; Madrid, Spain) for 15 min at maximum power (1150 
W) and for 15 min at medium power (900 W). Background blocking was performed 
with 1 : 20 normal goat serum (Dako, Glostrup, Denmark) prior to incubation with 
specific antiserum. Tissue sections were incubated with different polyclonal antibodies 
specific for: NTR (kindly supplied by Dr JoséRodrigo),27 diluted to 1 : 1000, without 
microwave; iNOS (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A., sc-651), diluted 
to 1 : 100, with microwave; eNOS (Transduction Laboratories, San Jose, CA, U.S.A., 
N30030-610298), diluted to 1 : 200, without microwave; and nNOS (Chemicon 
International Inc., Temecula, CA, U.S.A., AB1632), diluted to 1 : 200, with microwave; 
NF-κB (p65) (Delta Biolabs, Campbell, CA, U.S.A., DB033), diluted to 1 : 500, with 
microwave. Sections were incubated overnight at 4 °C with the primary antiserum. The 
detection system used was the Envision method (Dako, K4011), consisting of a goat 
antirabbit immunoglobulin secondary antibody coupled to a peroxidaselabelled dextran 
polymer. Sections were incubated with this reagent for 30 min at room temperature and 
successively washed in TBS for 5 min and in 0.1 mol L-1 sodium acetate⁄acetic acid 
buffer, pH 6.0, for 5 min. Peroxidase activity was revealed using 0.03% 3,3’-
diaminobenzidine (Sigma), which shows black colour, or Vector Vip (Vector 
Laboratories, SK-4600), which shows purple colour.28 Both were in 0.1 mol L-1 sodium 
acetate⁄acetic acid buffer, pH 6.0, containing 2.5% nickel ammonium sulfate, 0.2% -D-
glucose, 0.04% ammonium chloride and 0.01% glucose oxidase. The reaction was 
stopped by a wash in TBS. Finally, sections were lightly counterstained with 
haematoxylin, dehydrated and mounted with DPX. 
The results of immunohistochemical expression for each of the three PV sera were 
assessed on a scale of 0 to 3+: (0), no expression; (1+), patchy and weak staining close 
to the membranes of acantholytic cells of the floor⁄or base of the blister; (2+), moderate 
linear staining at the same site; (3+), clear and strong staining at the same site. 
 
RESULTS 
Skin lesions in mice after pemphigus vulgaris serum and normal human serum 
injection 
Results were similar after injection of each of the three PV sera in mice (n = 3) (see 
Table 2). The administration of PV-IgG reproduced the disease in a localized form 14 h 
after injection in both clinical (3+ in all three mice) and histopathological form (3+ in 
all mice) (Fig. 1a, b). The administration of purified NHS-IgG to mice did not show 
clinical or histological detachment (Fig. 1h, i), and no staining for IgG by direct and 
indirect IF assays was detected (data not shown). 
 
Expression of NTR, iNOS, eNOS, nNOS and NF-κB (p65) in pemphigus vulgaris 
acantholytic cells after pemphigus vulgaris serum and normal human serum 
injection 
After PV-IgG administration to mice, expression of NTR was increased in acantholytic 
cells both at the base and at the roof of the blisters (2+ to 3+) (Fig. 1c) (Table 2). 
Staining for iNOS was also found in the acantholytic cells at the base and at the roof of 
the blisters (2+) (Fig. 1d). Surprisingly, the expression of cNOS was observed in 
acantholytic cells both at the base and at the roof of the blisters as well, with a stronger 
staining for nNOS (2+ to 3+) (Fig. 1f) than for eNOS (1+ to 2+) (Fig. 1e). Nuclear 
translocation of NF-κB was observed only in basal keratinocytes and acantholytic cells 
(Fig. 1g) (Table 2). It is interesting to note that the expression of NTR, iNOS, eNOS 
and nNOS was evident from the beginning of the acantholytic process even when 
blisters were not fully formed (Fig. 2a–d). 
After NHS-IgG injection into the mice no expression of NTR was observed (Fig. 1j). 
Furthermore, we found only scattered and very slight basal cell cytoplasmic staining for 
nNOS (Fig. 1m), and staining for eNOS in the epidermis was absent (Fig. 1l). Slight 
staining for iNOS was observed in the nucleus of basal and suprabasal cells (Fig. 1k), 
and NF-κB (p65) was detected only within the cytoplasm of basal and suprabasal 
keratinocytes (Fig. 1n). 
 
Effects of pemphigus vulgaris serum in mice pretreated with inhibitors 
Clinical and histological PV manifestations after PV-IgG injection were prevented by 
pretreatment with the TK inihibitor genistein (Fig. 3a, b), the nNOS inhibitor SMTC 
(Fig. 4a, f) and the nonselective NOS inhibitor L-NMMA (Fig. 4b, g). In contrast, 
pretreatment of mice with the eNOS inhibitor L-NIO (Fig. 4c, h), the iNOS inhibitor 
1400W (Fig. 4d, i) and the NF-KB inhibitor parthenolide (Fig. 4e, j) did not prevent 
clinical skin lesions (Table 2). Direct IF staining of biopsies demonstrated pericellular 
surface staining for IgG in both groups of mice (PV-IgG and inhibitors plus PV-IgG), 
demonstrating that pretreatment with inhibitors did not affect the binding of the 
pathogenic IgG to Dsg3 (data no shown). Indirect IF revealed circulating IgG with a 
pericellular staining pattern with titres ranging between 1 : 20 and 1 : 80 (data not 
shown). 
The skin of the mice injected with PV sera and pretreated with TK, nNOS or 
nonselective NOS inhibitors did not exhibit expression of NTR in the epidermis (Figs 
3d and 4k, l). In contrast, only a weak decreased staining for NTR was found in mice 
injected with PV-IgG and pretreated with eNOS, iNOS and NF-κB inhibitors (1+ to 2+, 
1+ and 1+, respectively) (Fig. 4m–o). Interestingly, NF-κB nuclear translocation, and 
iNOS and nNOS expression on the membrane of basal keratinocytes were prevented by 
the pretreatment with TK inhibitor genistein. Only a scattered and very slight basal cell 
cytoplasmic staining for nNOS was observed (Fig. 3c, e, f). 
 
DISCUSSION 
Acantholysis in PV is a complex immunological process in which several mechanisms 
take part. On the one hand, PV patients present Dsg-3-specific T cells, which may 
trigger the response of B cells, yielding the production of autoantibodies against Dsg3 
and⁄or Dsg1.29 PV-IgG binding to Dsg may trigger the acantholysis phenomenon in 
suprabasal keratinocytes through several mechanisms. These include: physical 
disruption of adhesion by blocking the adhesive interface of the Dsg (steric hindrance 
theory);30 the depletion of membranal Dsg pool and formation of aberrant and weak 
desmosomes, thereby causing cell–cell separation;31 activation of intracellular signal 
transduction pathways leading to a negative influence on the adhesive function of 
Dsg;4,32–36 separation of keratinocytes due to cytoskeleton shrinkage (basal cell 
shrinkage hypothesis);37 and apoptosis as a process of keratinocyte death.38–41 These 
hypotheses have been complemented with the Dsg compensation concept to understand 
how acantholysis in PV takes place.42 Also, we have recently demonstrated in vivo the 
involvement of the phosphoinositide signalling pathway using the transfer mouse 
model.5 This provides a strong support for the role of the phosphorylation of proteins by 
protein kinases in the molecular mechanism of acantholysis. 
In this study we investigated the expression of NOS isoforms and NTR and the nuclear 
translocation of NF-KB in acantholytic cells in a mouse model of PV. All of these 
molecules were expressed in PV lesions, and nuclear translocation of NF-KB was 
detected in basal cells of the epidermis in mice after PV-IgG injection. These findings 
are particularly interesting as they indicate an additional contribution of inflammatory 
mediators in PV. Although a possible role for NOS and NF-KB in several autoimmune 
disorders has been demonstrated,13,18 the presence of these signalling molecules in 
acantholytic cells of PV in vivo has not been previously described. Only isolated in 
vitro studies have detected the presence of iNOS in PV.43 Also, recent work from Brazil 
has demonstrated that pemphigus patients display increased serum NO levels associated 
with increased iNOS expression in the affected skin.44 What could trigger the increased 
expression of these molecules in PV lesions in our mouse model, and how could they 
work? 
Multiple factors are important in determining the dual role of NO in physiology and 
pathophysiology.13 Among these, the local concentration of NO is an important 
determinant of cytotoxicity. The picomolar amounts of NO produced by cNOS isoforms 
are sufficient for intra- and intercellular signalling, including homeostasis of the 
microvasculature, while the micromolar concentrations generated by high-output iNOS 
are microbicidal as well as pro-inflammatory and so damage the surrounding cells and 
tissues.13,45,46 Recent evidence has demonstrated that the expression of cNOS (eNOS 
and nNOS) is not restricted to endothelial and neuronal cells47,48 and that the expression 
of the eNOS and nNOS genes may be regulated by a variety of physiological and 
pathological stimuli.49 In this sense, the presence of NTR specifically on acantholytic 
cell membranes together with iNOS, eNOS and nNOS staining is particularly 
interesting. Although it is known that iNOS is a more potent producer of NO than cNOS 
(eNOS and nNOS),13 our findings suggest an important and additional role of nNOS in 
the nitration mechanisms in PV. Moreover, we have previously demonstrated that the 
pretreatment with a calmodulin-antagonist also prevented acantholysis. This finding is 
consistent with the participation of a calcium-calmodulindependent cNOS isoform as in 
nNOS, in acantholysis of PV.5 In an inflammatory environment, as observed in PV 
lesions, a high production of NO may interact with superoxide radical (O2-) to produce 
the tissue-damaging peroxynitrite (ONOO-), an unstable metabolite that rapidly nitrates 
tyrosine residues in proteins on cells.50 There is also evidence that specific proteins 
could be nitrated by NO synthesized by cNOS, in the same way that they are nitrated by 
a peroxinitrite generator.51 In line with this, protein tyrosine nitration by NO derived 
from nNOS has also been demonstrated to take part in the pathogenesis of hepatic 
encephalopathy.52
A further relevant finding from our study is related to the clinical, histological and 
immunohistochemical results when inhibitors were used. NF-κB, eNOS and iNOS 
inhibitors did not prevent the PV acantholytic process in mice, and was associated with 
a weak decreased expression of NTR in the epidermis. However, nNOS and nonspecific 
NOS inhibitors prevented PV-IgG-induced acantholysis, with no expression of NTR. 
These results demonstrate that synthesis of NO by nNOS, and the subsequent NTR 
production, may have a direct role in promoting the acantholytic process in PV, in 
addition to cooperating in the inflammation of epidermis as well as in the 
plasminogen⁄plasmin53 and complement systems.54
The reason why the inhibitor of nNOS and the nonspecific inhibitor of NOS 
pretreatment abolished clinical lesions in mice is not clear to us. Recently, upregulation 
of nNOS in HaCaT cells has been achieved with epidermal growth factor receptor 
(EGFR) ligands, and this upregulation was completely inhibited by EGFR antagonist.47 
Also, it has been demonstrated that PV-IgG induces EGFR activation, and EGFR 
inhibition prevents acantholysis.55 These issues are consistent with our observation that 
the TK inhibitor genistein inhibited nNOS expression. Moreover, it is interesting to note 
that NTR expression in the epidermis was prevented by pretreatment with the nNOS 
inhibitor, thus showing that tyrosine nitration of proteins by nNOS is involved in PV. In 
this sense, nNOS may participate in PV through signalling events, which allow specific 
changes leading to acantholysis. On the other hand, Mishra and Delivoria-
Papadopoulos56 have recently reported that the NO derived from nNOS may contribute 
to apoptosis, a process associated with acantholysis in PV.39–41 Nevertheless, more 
studies are necessary to understand how nNOS works in PV lesions, and why its 
presence is necessary for the acantholytic phenomenon to develop. 
In addition, our study demonstrates nuclear translocation of NF-KB and iNOS 
expression in basal acantholytic cells in PV lesions. However, the inhibition of these 
related signalling events did not completely prevent both acantholysis and NTR 
expression in epidermis. This may indicate that the NO produced by iNOS is not 
essential in PV acantholysis in our model. Consequently, its function in the PV 
blistering process may be related only to the creation of an inflammatory environment 
as has been described in other autoimmune diseases,17,18 but with no function on the 
adhesion of keratinocytes. In other immunological diseases, such as toxic epidermal 
necrolysis and Stevens–Johnson syndrome, tissue damage may be observed by 
upregulation of iNOS. In these cases, large amounts of NO formed by iNOS from 
inflammatory cells may cause the epidermal apoptosis and necrosis.57
In summary, we demonstrate an increased expression of NTR, iNOS, eNOS and nNOS, 
and nuclear translocation of NF-κB in acantholytic cells of PV. The absence of clinical 
and histological findings of PV after pretreatment with TK and nNOS inhibitors in our 
model provide compelling evidence that nNOS, in addition to TK, should also be 
considered as a potential therapeutic target in PV. Nevertheless, further studies will be 
needed to reveal the exact contribution of the inflammatory mediators and specifically 
that of nNOS in the development of PV. 
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Table 1. Characteristics of PV and NHS sera 
Sera IP IIF ELISA 
PV1 Dsg1+ and Dsg3+ 1 : 640 Dsg1: 60, Dsg3: 173 
PV2 Dsg1+ and Dsg3+ 1 : 320 Dsg1: 189, Dsg3: 77 
PV3 Dsg1+ and Dsg3+ 1 : 640 Dsg1: 77, Dsg3: 169 
NHS No bands Negative Dsg1: < 20, Dsg3: < 20 
Dsg, desmoglein; ELISA, enzyme-linked immunosorbent assay; IIF, 
indirect immunofluorecence; IP, immunoprecipitation; NHS, normal 
human serum; PV, pemphigus vulgaris 
 
 
Table 2. Clinical, histological and immunohistochemical findings after PV-IgG or PV-IgG plus 
inhibitors 
 PV lesions Acantholysis NTR iNOS nNOS eNOS NF-xB 
NHS-IgG 0 0 0 Nuclear staining
Slight basal 
cell 
cytoplasmic 
staining 
0 Cytoplasmic staining 
PV-IgG 3+ 3+ 2+ to 3+ 2+ 2+ to 3+ 1+ to 2+ 2+ to 3+ 
SMTC + PV-IgG 0 0 0 ND ND ND ND 
L-NMMA + PV-
IgG 0 0 0 ND ND ND ND 
L-NIO + PV-IgG 3+ 3+ 1+ to 2+ ND ND ND ND 
1400W + PV-IgG 3+ 3+ 1+ ND ND ND ND 
Parthenolide + 
PV-IgG 3+ 3+ 1+ ND ND ND ND 
Genistein + PV-
IgG 0 0 0 
Slight 
nuclear 
staining
Slight basal 
cell 
cytoplasmic 
staining 
ND ND 
 
PV, pemphigus vulgaris; NTR, nitrotyrosine residues; iNOS, inducible nitric oxide synthase; 
nNOS, neural nitric oxide synthase; eNOS, endothelial nitric oxide synthase; NF-κB, nuclear 
factor κB; NHS, normal human serum; SMTC, nNOS inhibitor; L-NMMA, nonselective NOS 
inhibitor; L-NIO, eNOS inhibitor; ND, not done. 
 Figure 1. All mice injected with PV-IgG presented skin disease (3+) (positive 
Nikolsky’s sign) (a) and suprabasal blisters (3+) (b). In addition, these mice presented 
moderate-strong linear staining (2+ to 3+) for NTR (arrow) (c) and nNOS (arrow) (f), 
and moderate linear staining (2+) for iNOS (arrow) (d) in the membrane of the 
acantholytic cells at the base and the roof of the blisters. However, only weak-moderate 
staining for eNOS (arrow) was observed (e) with a similar staining pattern. Moderate-
strong (2+ to 3+) nuclear translocation of NF-jB was found in basal cell of epidermis 
(arrow) (g). Those mice injected with NHS-IgG showed neither clinical lesions (h) nor 
suprabasal acantholysis (i). Also, staining for NTR (j) and eNOS (l) was absent, and 
scattered nuclear expression for iNOS (k) was observed. Interestingly, very slight basal 
cell cytoplasmic staining for nNOS (arrow) (m) was found. No nuclear translocation 
was detected (n). Figure 2 displays close-up pictures showing how each molecule is 
expressed. PV-IgG, administration to mice of IgG fraction from PV patients; NHS, 
administration into mice of IgG fraction from normal human serum; NTR, expression of 
nitrotyrosine residues; eNOS, expression of endothelial nitric oxide synthase; iNOS, 
expression of inducible nitric oxide synthase; nNOS, expression of neuronal nitric oxide 
synthase. Original magnification x 40 (b–f, i–m) and x 80 (g, n). 
 
 
 
 
 
 
 
 
 
 
 Figure 2. Close-up pictures of Figure 1c–f. It is interesting to note that the expression of 
NTR (arrow) (a), iNOS (arrow) (b), eNOS (arrow) (c) and nNOS (arrow) (d) was 
evident from the beginning of the acantholytic process even when blisters were not fully 
formed. In these cases, the molecules were expressed in the cytoplasm and close to the 
membrane of keratinocytes during the blistering process. Original magnification x 100. 
 
 
 
 
 
 
 
 
 
 
 Figure 3. When mice were pretreated with genistein TK inhibitor before PV-IgG 
administration, clinical lesions (a) and suprabasal acantholysis (b) were not found. 
Additionally, no nuclear translocation of NF-κB (c) was found. NTR staining was 
absent (d) and scattered staining of nucleus of basal and suprabasal cells for iNOS (e) 
was detected, the same as those samples of epidermis of mice injected with NHS. A 
very slight basal cell cytoplasmic expression and scattered staining of nucleus for nNOS 
(arrow) (f) could be observed, without expression on the membrane of basal cells. 
Original magnification x 40 (b, d–f) and x 80 (c). 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4. Clinical PV manifestations, suprabasal acantholysis and NTR expression 
were studied in mice pretreated with several inhibitors before PV-IgG injection. After 
administration of nNOS inhibitor SMTC (a, f, k) and nonselective NOS inhibitor L-
NMMA (b, g, l) no clinical detachment, suprabasal blistering or NTR expression could 
be detected. In contrast, pretreatment with eNOS inhibitor L-NIO (c, h, m), iNOS 
inhibitor 1400W (d, i, n) and NF-κB inhibitor parthenolide (e, j, o) did not abolish 
clinical and histological PV manifestations, and weak-moderate (1+ to 2+, or 1+) NTR 
staining on the floor and base of membrane cells was found (arrow). PV-IgG, 
administration to mice of IgG fraction from PV patients; NHS, administration to mice 
of IgG fraction from normal human serum; NTR, expression of nitrotyrosine residues; 
eNOS, expression of endothelial nitric oxide synthase; iNOS, expression of inducible 
nitric oxide synthase; nNOS, expression of neuronal nitric oxide synthase; SMTC, 
nNOS inhibitor; L-NMMA, nonselective NOS inhibitor; L-NIO, eNOS inhibitor; 
1400W, iNOS inhibitor; parthenolide, NF-κB inhibitor. Original magnification x 40 (f–
o). 
